Τίτλος:
A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The ‘PROTOR’ Study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background/Aim: Pancreatic neuroendocrine tumors (panNETs) are rare neoplasms with challenging disease management. We aimed to evaluate the progression-free survival (PFS) and overall response rate (ORR) in chemotherapy-naïve patients with unresectable or metastatic Grade (G) 1-2 panNETs treated with everolimus in the routine care in Greece. Patients and Methods: This was a multicenter, prospective, observational study. Eligible patients were recently (≤4 weeks) initiated on treatment with everolimus and were followed for up to 48 months. Results: Nineteen eligible patients (mean age 55.1 years) were enrolled. All patients had metastatic disease and 84.2% had G2 panNET. Everolimus was initiated in combination with somatostatin analogues in 84.2% of the patients. The mean everolimus treatment duration was 21.5 months. The median Kaplan-Meier-estimated PFS was 20.4 months (95% confidence interval=14.1-41.5). The ORR was 27.8%. The rate of everolimus-related adverse events was 84.2% (Grade ≥3: 31.6%). Conclusion: Everolimus displayed clinical benefit and a predictable safety profile in pancreatic neuroendocrine tumors. © 2022 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
Kaltsas, G.
Andreadis, C.
Kosmidis, P.
Mavroudis, D.
Pazaitou-Panayiotou, K.
Vaslamatzis, M.
Athanasiadis, I.
Περιοδικό:
ANTICANCER RESEARCH
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
angiopeptin; aspartate aminotransferase; everolimus; gamma glutamyltransferase; glycosylated hemoglobin; octreotide; somatostatin derivative; sunitinib; everolimus, ablation therapy; adult; Article; artificial embolization; cancer radiotherapy; cancer staging; clinical article; controlled study; diabetes mellitus; distal pancreatectomy; drug dose reduction; dyslipidemia; female; follow up; glucose blood level; Greece; human; hypertriglyceridemia; inoperable cancer; Kaplan Meier method; male; metastasis resection; middle aged; multicenter study; observational study; overall response rate; pancreas islet cell tumor; progression free survival; prospective study; side effect; stomatitis; treatment duration; clinical trial; neuroendocrine tumor; pancreas tumor; pathology; prospective study, Everolimus; Humans; Kaplan-Meier Estimate; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies
DOI:
10.21873/anticanres.15672
